Loading...
XHKG
1358
Market cap256mUSD
Dec 05, Last price  
1.33HKD
1D
-0.75%
1Q
-6.34%
Jan 2017
-34.16%
IPO
-61.45%
Name

PW Medtech Group Ltd

Chart & Performance

D1W1MN
XHKG:1358 chart
P/E
12.04
P/S
2.36
EPS
0.10
Div Yield, %
7.11%
Shrs. gr., 5y
-0.33%
Rev. gr., 5y
16.25%
Revenues
769m
+13.90%
331,541,000457,083,000608,059,000515,587,000319,583,000286,913,000310,813,000362,183,000247,352,000271,399,000536,826,000675,084,000768,903,000
Net income
151m
-1.57%
44,668,00077,905,000176,630,000208,582,000109,136,0004,519,000114,812,00081,982,000631,814,000739,120,000106,041,000153,184,000150,780,000
CFO
318m
+50.89%
24,906,00052,807,00086,100,000259,975,000266,762,999183,777,00097,705,00099,993,00078,204,00037,243,000269,233,000211,031,000318,426,000
Dividend
Nov 03, 20250.044 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PW Medtech Group Limited, an investment holding company, operates as a medical device company in the People's Republic of China. The company manufactures and sells infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets, light resistant infusion sets, intravenous cannula products, and insulin needles and pens. It also provides property management services. The company was formerly known as Pyholding Limited. PW Medtech Group Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
IPO date
Nov 08, 2013
Employees
1,187
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT